Transgene biotek Limited has formally notified the Bombay Stock Exchange (BSE) regarding the non-applicability of SEBI Regulation 32(1) compliance requirements for the quarter ended March 31, 2026. The communication, dated April 13, 2026, was addressed to the General Manager of BSE's Listing Compliance Department.

Regulatory Compliance Notice

The company's intimation relates to SEBI Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed entities to submit statements of deviation or variation for proceeds from various capital raising activities. This requirement is based on SEBI circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, and subsequent amendments.

Non-Applicability Confirmation

Transgene Biotek Limited confirmed that during the reporting quarter ended March 31, 2026, the company did not undertake any of the following activities:

• Public issues
• Rights issues
• Preferential issues
• Qualified Institutions Placement (QIP)

Due to the absence of these capital raising activities, the Statement of Deviation or Variation requirements under Regulation 32(1) are not applicable to the company for Q4FY26.

Filing Challenges

The company also highlighted a technical issue with the regulatory filing system, noting that they were unable to file under XBRL mode as the form does not allow NIL entries. This technical constraint necessitated the formal intimation to BSE through alternative communication channels.

Management Authorization

The intimation was formally signed and submitted by Dr. K Koteswara Rao, Chairman & Managing Director of Transgene Biotek Limited, ensuring proper management authorization for the regulatory communication.

Transgene Biotek Limited has officially communicated to BSE that Regulation 57 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 does not apply to the company for the quarter ended March 31, 2026. The notification, dated April 13, 2026, was addressed to the General Manager of BSE's Department of Corporate Services.

Regulatory Compliance Status

The company's non-applicability status stems from the fact that Transgene Biotek Limited has not issued any non-convertible securities. This fundamental aspect exempts the company from the specific regulatory requirements outlined in SEBI LODR Regulation 57.

Official Communication Details

The formal notification was submitted under the subject "Compliance under regulation 57 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the quarter ended 31.03.2026." The company specifically stated that the regulation is not applicable since there are no non-convertible securities for which interest, dividend, or principal is payable during the quarter.

Compliance Requirements Assessment

The company provided a clear assessment of the regulatory compliance requirements for Q4 FY26:

Management Authorization

The formal notification was signed by Dr. K Koteswara Rao, Chairman & Managing Director of Transgene Biotek Limited. The communication was directed to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, requesting the exchange to take the information on record.

This regulatory filing ensures transparency and compliance with SEBI's disclosure requirements, even when specific regulations are not applicable to the company's current business structure and securities profile.